AI SLN Forecast

Price Forecast:


Bearish<->Bullish


Bullish Case: Recent positive Phase 2 data and expectations for the upcoming Phase 3 trial increase optimism for SLN, with high demand for innovative cancer therapies likely driving the price upward.


Bearish Case: If the Phase 3 trial for zerlasiran fails or produces neutral results, investor confidence may decline sharply, resulting in significant price drops given the high implied volatilities associated with current options.


Potential Outcomes:

1. Successful Phase 3 trial: 50% chance of +40% price (+40% to +50% price increase).

2. Neutral results: 30% chance of flat performance.

3. Failed trial: 20% chance of -30% price drop.


Trading Oracle: Sign Up to access trading oracle trade ideas.


September 26, 2024


Silence Therapeutics Plc - Forecast

SLN        Silence Therapeutics Plc -
















Become a more profitable investor with AI optimized trading strategies






×

Chat with SLN


 Ask any question about SLN!